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Having established a method to dynamically control the cross-linking of natural fibrils, we will use the same biomechanical methods that we have used for natural tissues to evaluate the mechanics of the modified tissues. The next step will be to translate these approaches into a synthetic system with similarly controlled properties. Ultimately, this stepwise approach is expected to lead to the development of a fully synthetic fibrous composite with dynamically controlled stiffness. superfamily that is required for proper skeletal patterning and development in the vertebrate limb. Based on the homology of GDF-5 with other bone-inducing BMP family members, the inductive activity of a recombinant form of human GDF-5 (rhGDF-5) was evaluated in a series of in vitro assays and in vivo bone-formation models. The in vitro response to rhGDF-5 resulted in the formation of chondrogenic nodules in fetal rat calvarial cells cultured in the context of collagen or collagen/hyaluronate extracellular matrices. Matrices loaded with rhGDF-5 induced ectopic cartilaginous and osseous tissue when implanted in subcutaneous or intramuscular sites. In nonhuman primate long-bone-defect and spinalfusion models, rhGDF-5 combined with a mineralized collagen matrix induced bone formation in a manner equivalent to autogenous bone. These results highlight the unique potential of rhGDF-5 in a wide variety of orthopaedic applications.
Introduction
T h e skeletal elements of the vertebrate limb are derived during embryonic development from mesenchymal cells, which condense and initiate a differentiation program that results in the formation of cartilage and bone. I t is well established that members of the bone morphogenetic protein (BMP) family play a direct role in the developmental events that dictate skeletal patterning [1, 2] . Growth and differentiation factor-5 (GDF-5), also termed cartilage-derived morphogenetic protein-1 (CDMP-1) and MP52, is a member of the BMP family that defines a distinct structural and functional subgroup. GDF-5 shares 40-50 yo protein-sequence homology with the BMP-2 and BMP-7 (osteogenic protein-1, or OP-1) familymember subgroups and plays a pivotal role in the process of joint formation [3-61. A null mutation in gdf-5 at the mouse brachypodism (bp) locus disrupts the formation of approx. 30% of the joints of developing limbs, including the complete absence of joint development between the proximal and medial phalanges of the fore-and hindfeet [1, 5] . In addition to joint development, G D F -5 has shown activity in promoting the survival of dopaminergic neurons, inducing angiogenesis in vivo, and in tendon/ligament morphogenesis [7-91. Based on the homology of GDF-5 with other BMP family members and the activity of this growth factor in skeletal development, a recombinant version of human GDF-5 (rhGDF-5) was evaluated as a potential inductive component of a matrix/growth factor bone-graft substitute.
Materials and methods

Growth factors and matrix components
Purified rhGDF-5 was provided by Hoechst Marion Roussel (Kawagoe, Saitama, Japan) and Biopharm (Heidelberg, Germany) and was prepared from prokaryotic expression systems as described previously [4, 10] . Demineralized bone preparations were isolated as described previously [ll] . Type-I bovine collagen was purchased from Kensey-Nash (Exton, PA, U.S.A.) or Collagen Corp. (Palo Alto, CA, U.S.A.). Hyaluronate was purchased from Lifecore Biomedical (Chasca, MN, U.S.A.).
Matrix and matridgrowth factor fabrication
Type-I collagen, mineralized collagen (Healos@) and collagen/hyaluronate matrices were prepared as described previously [12, 13] . Stock rhGDF-5 solution was diluted in 2 0 m M sodium acetate buffer, p H 4.0, prior to adding to sterile collagen, mineralized collagen or collagen/hyaluronate matrices at concentrations ranging from 10 to 1500 pg/cm3 of matrix material. Matrix/GDF-5 combinations were then lyophilized and stored at 4 "C.
In vivo assays Rat soft-tissue implants
Matrix/growth factor combinations were implanted either subcutaneously in the thoracic region or intramuscularly in posterior tibia1 muscle pouches created by blunt dissection in 8-week-old male Sprague-Dawley rats. At 14-21 days postsurgery, implants were harvested, weighed and processed for routine histology (fixed in 10 % formalin, paraffin-embedded, sectioned to 6 pm and haematoxylin-and eosin-stained). Alternatively, implants were extracted and assayed for alkaline phosphatase activity using commercially available assay kits (Sigma, St. Louis, MO, U.S.A.).
Primate long-bone-defect model Bilateral 1 .5-cm osteotomy defects were created in the mid-diaphysis of the fibulae of 16 skeletally mature male baboons (Papio cynocepthalus ; four animals per group). Defects were stabilized with a customized stainless steel plate and implanted unilaterally with two strips (1.8 x 1 .O x 0.6 cm, 1.1 cm3 volume) of mineralized collagen matrix with or without three dose levels of rhGDF-5 (10, 100 and 1000 pg/cm3 or total dose of 22, 220 and 2200pg). Contralateral defects were left as untreated controls. Radiographic analysis was performed immediately after surgery and every 4 weeks thereafter. Implant materials were retrieved at 21 weeks for qualitative and quantitative histological analysis. Quantitative histomorphometric analysis (QHMA) was performed using a BioQuant Four Image Analysis system. Representative slides were selected for examination at 1.6 x original magnification. T h e defect was centred within the microscopic field and all area measurements (mm') were made within this stand-ardized area. Both the percentage of new bone (PNB) and percentage of residual defect (PRD) were measured.
Primate spinal-fusion model A non-instrumented, posterolateral lumbar intertranverse process fusion of one motion segment was performed in 36 skeletally mature female baboons using mineralized collagen matrix with or without rhGDF-5 (500 and 1500pg/cm3 of matrix) or autograft (5 cm3 per side) harvested from the iliac crest. Vertebrae lumbar (L)2-L6 were exposed through a posterior approach and the graft site was prepared bilaterally by decortication of the transverse processes. Two strips of graft material per side (5 cm3 per strip) were placed across the transverse processes of L4 and L5 for total doses of 5 and 15 mg of rhGDF-5 per side at the 500 and 1500 pg/cm3 concentrations, respectively. Radiographic evaluation was performed at 0, 8, 12, 16 and 20 weeks post-treatment. At 20 weeks, spines were harvested for ex vivo radiographic, computerized tomographic (CT) and qualitative histological evaluation. Radiographic and qualitative histological data were evaluated blind and correlated with reconstructed C T data to determine the extent and quality of each fusion mass. Histological evidence of fusion was assessed through review of stained thin plastic sections, unstained and backlit thick sections, and blocks of fixed calcified tissue. Histological scores were assigned to each animal based on independent interpretation of the response achieved on each side of the motion segment. Four performance outcomes were assessed : complete fusion, discontinuous fusion mass, periosteal reactive bone formation or no bone formation. The left and right side outcomes were paired into equivalent ranking of left/right matched observations to form ten levels of response score (scored 0-9). A frequency of 100 yo complete bilateral fusion in nine animals would result in a maximum total score of 81.
Statistical methods
In the long-bone model, paired t tests were performed on the QHMA data to compare PNB and PRD in treated and untreated sites within each treatment group. In the spinal-fusion model, a rule of reasonable decision was the primary criterion for scoring equivalence between treatment groups. Based on a prospective decision, equivalence existed for groups with total scores that were within & 8 points. A Wilcoxon rank sum test for non-uniform samples was used to test the null hypothesis that mean responses to two treatments was equivalent. Significance was tested at a = 0.05.
Results
In vitro activity of rhGDF-5 In contrast to most BMP family members, the response of cultured cells to GDF-5 as measured by alkaline phosphatase activity has been shown previously to be diminished and restricted to a subset of osteoblast-like cell lines such as ROB-C26 [lo]. GDF-5 has also been shown to stimulate mesenchyme aggregation and chondrogenesis in rat limb-bud cells in vitro [14] . Using fetal rat calvarial cells as an alternative cell source for osteo-and chondro-progenitor cells [15, 16] , we have observed that rhGDF-5 stimulates the in vitro formation of chondrogenic nodules in cells that are seeded in the context of type-I collagen or collagen/hyaluronate extracellular matrix (ECM) components. The dependence of this in vitro response on specific components of the ECM was unique to rhGDF-5 in comparison with other members of the BMP family (M. Heidaran and R. C. Spiro, unpublished work).
In vivo activity of rhGDF-5 GDF-5 has been previously shown to induce ectopic cartilage and bone formation in rodents in vivo [ 141. Collagen/hyaluronate matrices loaded with rhGDF-5 (30pg) and implanted intramuscularly in rats for 21 days formed ectopic cartilaginous foci within the matrix. Cells with distinct chondrocyte-like morphology were observed within the foci and were surrounded by an extensive metachromatic staining matrix. Subcutaneous implants of collagen or mineralized collagen matrices loaded with rhGDF-5 (10 and 100 pg) showed a dose-dependent increase in alkaline phosphatase activity. The alkaline phosphatase activity induced by 1OOpg of rhGDF-5 was an order of magnitude less than that observed with comparable amounts of demineralized bone powder (0.87 k0.4 versus 13.5 f 2.1 nmol/min per mg of implant, respectively). In general, the ectopic bone formation in response to rhGDF-5 was less than that observed with other BMP family members (A. Thompson and R. C. Spiro, unpublished work).
In the primate long-bone-defect model, a 1.5-cm fibular defect treatedwith rhGDF-5 -loaded mineralized collagen matrices (1 0, 100 and 1OOOpg of rhGDF-5 per cm3 of matrix) showed radiographic evidence of healing that stratified with dose ( Figure 1 ). In the primate spinal fusion model, the implantation of mineralized collagen matrices containing 500 pg/cm3 rhGDF-5 induced the highest frequency of bilateral fusion, as judged by radiographic/CT analysis (Figure 2) . Four bilateral fusions and two unilateral fusions were observed in this group based on assessment by two independent reviewers. Surprisingly, only one of the 1500 pg/cm3 rhGDF-5-treated specimens was scored as a bilateral fusion and only two achieved unilateral fusion, with disagreement between the two reviewers on one of the unilateral fusions. Autograft-treated specimens were scored as bilateral fusions in two specimens and as unilateral fusions in four specimens, with disagreement between the reviewers on two of the unilateral fusion specimens. None of the mineralized collagen-matrix-alone-treated specimens had radiographic/CT evidence of fusion.
Histological evaluation revealed that all specimens showed some evidence of new bone, ranging from complete bony fusion across the motion segment to limited focal periosteal reactive bone formation. The matrix 500 pg/cm3 rhGDF-5 specimens showed the most robust bone formation, with well-organized fusion masses consisting of inner zones with a high volume of trabecular bone, lamellar in nature, and a pro- visional cortex with well-formed osteons (Figure  3) . Three specimens had bilateral fusion, two unilateral fusion and four had discontinuous fusion masses that showed zones of fibrous or cartilaginous tissue at the level of the intervertebral disc. Higher magnification of the bone mass showed increased osteoblast activity and abundant marrow spaces with fatty haematopoietic marrow. There was no evidence of residual matrix in any specimens in this group. The histological fusion score for this group was 63 out of a possible 81, with an average score of 7. The matrix 1500 pg/cm3 rhGDF-5 specimens generally showed less bone formation and appeared to undergo a more complex process of healing, both with respect to cellular constituents and the timing of bone formation and resorption. Modelling and remodelling activity appeared to have been more robust and at an earlier time point than in the other groups, resulting in a bone mass of lower volume at 20 weeks. This group consistently showed a hypercellular haematopoietic marrow with a decreased ratio of fat to marrow. No bilateral fusions and only one unilateral fusion were observed in this group and the average fusion score was 4.3 with a total score of 34 out of a possible 72 (one animal lost). No residual matrix was apparent in any of the specimens of this group. Autografttreated specimens were seen to have large bony fusion masses consisting of irregular lamellar trabecular bone that contained normocellular haematopoietic marrow and well-developed provisional cortices. Overall cellularity and osteoblast numbers were decreased compared with the mat- rix 500 pg/cm3 rhGDF-5 group. Two bilateral and two unilateral fusions were observed in this group. Discontinuous fusions showed regions of dense hyalinized fibrocollagenous connective tissue. The average fusion score for this group was 6.5, with a total score of 59 out of a possible 81.
Specimens treated with matrix alone showed only minimal evidence of new bone formation that was limited to the transverse process origins. The average fusion score for this group was 2.9, with a total score of 26 out of a possible 81. Arrows point to regions of teardrop-shaped fusion mass that bridge the motion segment.
Discussion
As a subgroup-defining member of the BMP family of proteins, GDF-5 was initially distinguished from other family members based on a divergence of primary sequence, a unique expression pattern in developing skeletal systems and on the abnormalities that result from sequence mutations [l-61. Subsequent studies that identified preferential receptor utilization, angiogenic activity, tendon and ligament induction, and neuronal-cell survival activity of GDF-5 added further distinctions [7-lo]. The results presented in this current study have also extended the list of unique properties and activities of GDF-5. The predominance of cartilaginous-like tissue observed in response to rhGDF-5 in the in vitro culture and in vivo implantation studies is consistent with the proposed role for GDF-5 in chondrogenesis and endochondral bone formation [14] . It has been suggested that the diverse biological functions documented for GDF-5 may relate to a more restricted utilization of signalling receptors compared with other BMP proteins [lo].
The influence of specific ECM such as type-I collagen and hyaluronate on the in vitro response to rhGDF-5 observed here suggests an additional level of control over the function and activity of this growth factor. All of the described biological activities of GDF-5 (chondrogenesis, osteogenesis, angiogenesis, etc.) can also be influenced directly by components of the ECM [17]. The synergy demonstrated between components of the ECM and the response to rhGDF-5 can be expected to have a direct impact on the activity and efficacy of matrix/rhGDF-5 combinations in tissue-grafting indications.
An important factor in the design of a successful matrix/growth factor combination for tissue grafting is the optimization of the conductive properties of the matrix with the inductive activity of the growth factor. These attributes come ' ready-made ' and pre-optimized ' in an autogenous grafting material such as autograft. Incorporating them into an engineered substitute requires that the response to the inductive agent be balanced with the conductive activity and persistence of the matrix at the defect site. This can be accomplished through the manipulation of physical properties of the matrix that affect persistence or by tailoring the response to the growth factor by adjusting the loading concentration. Given the dependence of the cellular response to rhGDF-5 on an interaction with ECM components, matrix persistence and growth factor concentration become even more important for the performance of a matrix/rhGDF-5 tissue graft. The primate bone studies described in this report have provided direct evidence for these concepts.
In the primate long-bone-defect model, a clear trend towards a dose-dependent response to mineralized collagen/rhGDF-5 was observed over a 2-log increase (10-1000 pg/cm3) in rhGDF-5 concentration. The formation of radio-opaque tissue and the frequency of union and maturity of the reparative bone at 21 weeks all appeared to increase with higher rhGDF-5 concentrations (Figure 1) . This was not the case, however, in the primate spinal fusion study. While equivalence to autograft was demonstrated at 500 pg rhGDF-5 per cm3 of matrix (5-mg total dose per side; Figures 2 and 3) , a 3-fold increase in rhGDF-5 (1 500 ,ug/cm3, 15 mg total dose per side) markedly decreased the efficacy of this matrix/growth factor combination ( Figure 2 ). The exact mechanism underlying the poor performance at this dose level is not clear, but histological evidence at 20 weeks suggests a more complex healing process with respect to cellular constituents and the timing of bone formation and matrix resorption.
The mineralized collagen matrix (Healosm) used in the in vivo studies of this report was designed as an osteoconductive matrix to be used in conjunction with endogenous or exogenous osteogenic and osteoinductive components. It incorporates desirable physical attributes (continuous pore structure, high wet strength and radiolucency) with osteoconductive properties and resorption characteristics that allow it to be replaced completely by new bone [13] . It has performed equivalently to autograft in previous longbone-defect and spinal-fusion studies when mixed with a bone marrow aspirate [13, 18] . The performance of the mineralized collagen matrix in conjunction with an inductive growth factor clearly relies on a proper balance between matrix resorption and bone formation. This balance is even more critical in light of the enhanced activity observed with rhGDF-5 in combination with collagen-based matrices.
